Tactics of the management of patients with atypical endometrial hyperplasia

Abstract

This review deals with modern aspects of the management of patients with endometrial hyperplasia with atypia. There are considered modalities of different types of drug therapy and surgical treatment.

Keywords

endometrial hyperplasia / hyperplasia with atypia / hormone therapy

References

[1] Kurman R.J., Carcangiu M.L., Herrington C.S., Young R.H. (Eds.). WHO Classification of Tumours of Female Reproductive Organs. 4th Ed. Lyon: IARC; 2014.

[2] Адамян Л.В. (ред.). Клинические рекомендации «Cочетанные доброкачественные опухоли и гиперпластические процессы матки (миома, аденомиоз, гиперплазия эндометрия)»: Проект. М.; 2015. www.reproductive-congress.ru

[3] Kurman R.J., Kaminski P.F., Norris H.J. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer. 1985; 56: 403-12.

[4] Reed S.D., Newton K.M., Clinton W.L., Epplein M., Garcia R., Allison K. et al. Incidence of endometrial hyperplasia. Am. J. Obstet. Gynecol. 2009; 200: 678.e1-6.

[5] Mutter G.L., Bergeron C., Deligdisch L., Ferenczy A., Glant M., Merino M. et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod. Pathol. 2008; 21: 591-8.

[6] Gallos I.D., Alazzam M., Clark T.J., Faraj R., Rosenthal A.N., Smith P.P., Gupta J.K. Management of Endometrial Hyperplasia. Green-top Guideline No. 67. RCOG/BSGE Joint Guideline; 2016.

[7] Lacey J.V. Jr, Sherman M.E., Rush B.B., Ronnett B.M., Ioffe O.B., Duggan M.A. et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J. Clin. Oncol. 2010; 28: 788-92.

[8] Trimble C.L., Kauderer J., Zaino R., Silverberg S., Lim P.C., Burke J.J. 2nd et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group Study. Cancer. 2006; 106: 812-9.

[9] Mourits M.J., Bijen C.B., Arts H.J., ter Brugge H.G., van der Sijde R., Paulsen L. et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet. Oncol. 2010; 11: 763-71.

[10] American College of Obstetricians and Gynecologists. Supracervical hysterectomy. ACOG Committee Opinion No. 388. Obstet. and Gynecol. 2007; 110: 1215-7.

[11] Indermaur M.D., Shoup B., Tebes S., Lancaster J.M. The accuracy of frozen pathology at time of hysterectomy in patients with complex atypical hyperplasia on preoperative biopsy. Am. J. Obstet. Gynecol. 2007; 196: e40-2.

[12] ASTEC Study Group, Kitchener H., Swart A.M., Qian W., Amos C., Parmar M.K. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373: 125-36.

[13] Benedetti Panici P., Basile S., Maneschi F., Lissoni A., Signorelli M., Scambia G. et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J. Natl. Cancer Inst. 2008; 100: 1707-16.

[14] Parker W.H., Feskanich D., Broder M.S., Chang E., Shoupe D., Farquhar C.M. et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. J. Obstet. Gynecol. 2013; 121: 709-16.

[15] Vilos G.A. Intrauterine surgery using a new coaxial bipolar electrode in normal saline solution (Versapoint): a pilot study. Fertil. and Steril. 1999; 72: 740-3.

[16] Edris F., Vilos G.A., Al-Mubarak A., Ettler H.C., Hollett-Caines J., Abu-Rafea B. Resectoscopic surgery may be an alternative to hysterectomy in high-risk women with atypical endometrial hyperplasia. J. Minim. Invasive Gynecol. 2007; 14: 68-73.

[17] Gallos I.D., Yap J., Rajkhowa M., Luesley D.M., Coomarasamy A., Gupta J.K. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am. J. Obstet. Gynecol. 2012; 207: 266.e1-12.

[18] Reed S.D., Newton K.M., Garcia R.L., Allison K.H., Voigt L.F., Jordan C.D. et al. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet. and Gynecol. 2010; 116: 365-73.

[19] Gallos I.D., Shehmar M., Thangaratinam S., Papapostolou T.K., Coomarasamy A., Gupta J.K. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am. J. Obstet. Gynecol. 2010; 203: 547.e1-10.

[20] Gallos I.D., Krishan P., Shehmar M., Ganesan R., Gupta J.K. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. Hum. Reprod. 2013; 28: 1231-6.

[21] Dorigo O., Aoyama C., Ostrzega N., Balzer B.L., Rao J. et al. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol. Oncol. 2012; 124: 542-8.

[22] Gallos I.D., Krishan P., Shehmar M., Ganesan R., Gupta J.K. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Hum. Reprod. 2013; 28: 2966-71.

[23] ACOG Practice Bulletin number 65: Management of endometrial cancer. Obstet. and Gynecol. 2006; 107: 952.

[24] Park J.Y., Lee S.H., Seong S.J., Kim D.Y., Kim T.J., Kim J.W. et al. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol. Oncol. 2013; 129: 7-11.

[25] National Institute for Health and Care Excellence. Fertility: Assessment and Treatment for People with Fertility Problems: NICE Clinical Guideline 156. Manchester: NICE; 2013.

[26] Kelly P., Dobbs S.P., McCluggage W.G. Endometrial hyperplasia involving endometrial polyps: report of a series and discussion of the significance in an endometrial biopsy specimen. Br. J. Obstet. Gynaecol. 2007; 114: 944-50.

RIGHTS & PERMISSIONS

Eco-Vector